| Autor: |
Ghia, P., Munir, T., Burger, J., Seymour, J. F., Rogers, K., Huang, H., Moreno, C., Neumayr, L., Abbazio, C., Sharman, J. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p464-466, 3p |
| Abstrakt: |
Ibrutinib (Ibr) for treatment of relapsed-refractory (R/R) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison of 3 randomized phase 3 trials B Introduction I : i b Ibr is a standard therapy for CLL with demonstrated efficacy in first-line and R/R settings. B Methods: b Individual patient data (IPD) of Ibr-treated pts from RESONATE (NCT01578707) were separately match-adjusted to Ibr-treated arms of 1) ALPINE (NCT03734016) and 2) ELEVATE-RR (NCT02477696) for key baseline characteristics: age >=75 y, bulky disease, >=3 or >=4 prior treatments, b SB 2 sb microglobulin >3.5 mg/L, and del(11q) or del(17p). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text